What Nexome Genomics does

Nexome Genomics is a US-based biotechnology company that operates a cloud-based next-generation sequencing (NGS) analytics and reporting platform aimed at healthcare institutions. Its product stack centers on two core offerings: Nexome Scan, a cloud-based genomic data storage system, and Nexome Discover, which generates on-demand diagnostic and prognostic reports from sequencing data. Layered on top of this platform is the proprietary NexoSeq panel family — a pan-cancer Oncology panel of roughly 200 genes developed using The Cancer Genome Atlas (TCGA) data covering more than 6,000 tumors, plus indication-specific panels for breast (~50 genes), liver, prostate (40 genes), and lung cancer. The company also offers traditional molecular diagnostics services, including Fluorescence in Situ Hybridization (FISH), microarray/qPCR-based gene expression and mutation detection, and whole-genome/exome sequencing services. Operations are run from an integrated molecular diagnostics laboratory in Gaithersburg, MD (close to NIH) and a development and LDT facility in Beijing, China.

The company's business model combines cloud-based analytics services delivered to medical centers, hospitals, physician offices, and clinical laboratories with professional-services revenue from its in-house laboratory offerings. Its primary customer segments are healthcare provider institutions and clinical/government laboratories, with research institutions listed as a secondary segment. Go-to-market is direct B2B sales of on-demand analytics and reporting, supported by strategic proximity to NIH and an advisory network that includes Dr. Yidong Chen (computational biology, NIH/UT Health San Antonio) and Ethan Tu (founder of Taiwan AI Labs, former Microsoft AI R&D director). Pricing is not publicly disclosed, no funding rounds are on record, and the company is privately held with 1-10 employees, making its commercial scale difficult to gauge from public information.

Name

Nexome Genomics

Legal name

Noxome Genomics Inc.

Website

https://nexomegenomics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Nexome Genomics operates a cloud-based NGS analytics and reporting platform that delivers on-demand diagnostic and prognostic reports to medical centers, hospitals, physician offices, and clinical laboratories, supported by proprietary NexoSeq cancer panels and lab services across US and China facilities.

Ownership category

akta.pro rank

Product category

Clinical Genomic Data Analytics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Genomic data analytics
• Next-generation sequencing
• Molecular diagnostics
• Precision medicine
• Cancer genomics panels

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cloud-based Analytics Services: On-demand access to precision medicine analytics solutions with diagnostic and prognostic reporting capabilities provided to healthcare institutions.
2. Molecular Diagnostics Laboratory Services: Clinical diagnostic services including FISH testing, microarray analysis, sequencing services (whole genome, exome, targeted panels), and cytogenetic examination for genetic testing and cancer diagnosis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Nexome Genomics provides cloud-based, integrated next-generation sequencing (NGS) analytics solutions that enable healthcare institutions—medical centers, hospitals, physician offices, and clinical laboratories—to generate on-demand diagnostic and prognostic reports from genomic data. Its offering combines a cloud genomic data storage and reporting platform (Nexome Scan and Nexome Discover) with proprietary NexoSeq cancer panels and molecular diagnostics laboratory services such as FISH, microarray/qPCR, and comprehensive sequencing.

Product overview

Nexome Genomics offers a cloud-based, integrated NGS data analytics and reporting platform consisting of two core products: Nexome Scan for genomic data storage and Nexome Discover for on-demand diagnostic and prognostic report generation. The platform is complemented by NexoSeq proprietary cancer panels (Oncology, Breast Cancer, Liver Cancer, Prostate Cancer, and Lung Cancer) that utilize NGS technologies for cancer diagnosis. Additional services include Fluorescence in Situ Hybridization (FISH), microarray and qPCR for gene expression and mutation detection, and comprehensive sequencing services. The solution shifts the traditional person-to-person service model to an online service offering genetic diagnostics through a secure and trusted reporting system.

Differentiator

Problem solved

Functional benefit

Brands

• Nexome Scan: Cloud-based genomic data storage system providing on-demand diagnostic and prognostic report generation.
• Nexome Discover
• NexoSeq

Products and services

• Nexome Scan Cloud-based genomic data storage platform providing on-demand, secure storage infrastructure for next-generation sequencing (NGS) datasets used by healthcare institutions to power precision medicine reporting.
• Nexome Discover On-demand diagnostic and prognostic report generation system that produces interpretive clinical reports from genomic data for medical centers, hospitals, and physician offices, supporting disease diagnosis, prognosis, and targeted therapy selection.
• NexoSeq Oncology (Pan-Cancer Panel) Proprietary pan-cancer NGS panel targeting approximately 200 genes linked to major mutations across multiple cancer types, designed using The Cancer Genome Atlas (TCGA) data and in-house cancer profiling results.
• NexoSeq Breast Cancer Panel Targeted NGS panel for breast cancer diagnosis covering approximately 50 genes, including BRCA1, BRCA2, and additional genes linked to breast cancer based on large-scale breast cancer profiling and genome-wide association studies.
• NexoSeq Liver Cancer Panel Comprehensive NGS panel for liver cancer covering genes mutated in hepatocellular carcinoma (HCC), including TP53, beta-catenin, MYC, FGF19, and TERT promoter region mutations, plus genes in the WNT, TGF beta, and JAK1 pathways.
• NexoSeq Prostate Cancer Panel Focused NGS panel of 40 genes associated with prostate cancer, including TP53, TMPRSS2, PTEN, AR, and hereditary prostate cancer genes BRCA1, BRCA2, and CHEK2, analyzed using NGS with insertion/deletion detection.
• NexoSeq Lung Cancer Panel Targeted NGS panel for non-small cell lung cancer (NSCLC) diagnosis that identifies mutations in EGFR, KRAS, and ALK to determine eligibility for tyrosine kinase inhibitor therapy such as erlotinib.
• Fluorescence in situ Hybridization (FISH) Full-service molecular cytogenetics testing predominantly for oncology and prenatal medicine applications, including ERBB2 amplification testing for breast and stomach cancer, ALK translocation and ALK-EML4 fusion testing in lung cancer, and BCR-ABL1 fusion detection in chronic leukemias.
• Microarray and qPCR Gene Expression and Mutation Detection Gene expression and mutation detection services using versatile microarray platform testing and qPCR, supporting genetic testing, cancer diagnosis, and companion diagnostics for personalized medicine.
• Sequencing Services Comprehensive sequencing services including whole genome and exome analyses, comprehensive as well as targeted disease-specific panels, and a full range of next-generation sequencing (NGS) analytics solutions.

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

Three partnerships are on record, tiered core and moderate.

• National Institutes of Health (NIH)coreStrategic or Co-development PartnerStrategic proximity and interaction with NIH enables Nexome to stay at the forefront of diagnostic medicine and closely monitor trends in molecular cytogenetics. NIH is described as one of the world's leading centers for biological research.
• Academic, Biotechnology and Clinical Community PartnerscoreStrategic or Co-development PartnerSpirited connections with strategic partners in academic, biotechnology and clinical communities enable proactive approach to development and validation of diagnostic tests.
• Taiwan AI LabsmoderateStrategic or Co-development PartnerEthan Tu, founder of Taiwan AI Labs and former Microsoft AI R&D director, serves as an advisor. Taiwan AI Labs focuses on machine learning and AI for precision medicine, medical image, genome analysis and medical devices.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexome Genomics